Aims/hypothesis Oxidative stress is a promising target in diabetes-associated vasculopathies, with inhibitors of NADPH oxidases (NOX), in particular isoforms 1 and 4, shown to be safe in early clinical development. We have explored a highly relevant late-stage intervention protocol using the clinically most advanced compound, the NOX1/4 inhibitor GKT137831, to determine whether end-organ damage can be reversed/attenuated when GKT137831 is administered in the setting of established diabetic complications. Methods GKT137831 was administered at two doses, 30 mg kg −1 day −1 and 60 mg kg −1 day −1
Introduction
The development of vascular complications, including atherosclerosis and kidney disease, is accelerated in diabetes [1] . Although a range of factors that contribute to the progression Electronic supplementary material The online version of this article (doi:10.1007/s00125-017-4215-5) contains peer-reviewed but unedited supplementary material, which is available to authorised users. of diabetic complications have been identified, increased formation of reactive oxygen species (ROS), including by NADPH oxidase (NOX), is considered critically important. A major source of ROS is derived from members of the NOX family [2] . Three primary NOX isoforms have been identified in the mouse, NOX1, NOX2 and NOX4, and are considered to be relevant to vascular and renal disease [3, 4] . In the setting of diabetes, NOX1 has been shown to exert deleterious effects in retinopathy and macrovascular disease, whereas NOX4 has been shown to play a critical role in the development of diabetic nephropathy. Global Nox1 deletion attenuated atherosclerosis in diabetes [5] and genetic deletion of Nox4 globally and specifically in podocytes attenuated the development of kidney disease [6] .
Therapeutic targeting of NOX-derived ROS had limited success initially, largely because of the lack of specific inhibitors. Early studies with apocynin and diphenyleneiodonium (DPI) demonstrated reductions in ROS production and attenuation of disease [7, 8] . However, both agents were shown to have significant off-target effects, in part because they are not specific NOX inhibitors [9, 10] . More recently, specific NOX inhibitors have been developed, including the NOX1/4 inhibitor GKT137831 (Genkyotex, Geneva, Switzerland) . This compound does not affect NOX2-mediated phagocyte function and thus appears to be superior to other NOX/ROS inhibitors [11] . Previously, our group demonstrated that administration of GKT137831 to diabetic ApoE −/− mice attenuated the development of diabetesassociated atherosclerosis and diabetes-associated kidney disease [5, 6, 12] . We hypothesised that administration of GKT137831 in a model of diabetic macro-and microvascular disease would attenuate or even reverse disease progression. In these studies, GKT137831 was administered as a preventive intervention, starting immediately after diabetes induction with streptozotocin (STZ). A clinically more relevant question is whether NOX1/4 inhibition can arrest, attenuate or even reverse end-organ injury once disease progression is established. Therefore, the overall aim of the current study was to explore if pharmacological inhibition of NOX1 and NOX4 in mice with established diabetic complications, including both macrovascular and renal disease, could attenuate or indeed reverse disease progression. We used the STZ-diabetes model in ApoE −/− mice and two doses of the specific NOX1
and NOX4 inhibitor GKT137831 administered in a setting of established diabetic nephropathy and atherosclerosis.
Methods
More detailed methods can be found in the electronic supplementary material (ESM). [5, 13, 14] . Mice were excluded from the study if they had a blood glucose reading below 15 mmol/l 1 week after diabetes induction. At 19 weeks post induction of diabetes, systolic blood pressure was assessed by a non-invasive tail cuff system in conscious mice [15] . At 10 and 20 weeks after induction of diabetes, mice were placed individually into metabolic cages (Iffa Credo, L'Arbresele, France) for 24 h urine collection [6] . After 20 weeks, the animals were anaesthetised by i.p. injections of sodium pentobarbitone (Euthatal, 100 mg/kg body weight; Sigma-Aldrich, Castle Hill, NSW, Australia). HbA 1c was measured in erythrocyte lysates by HPLC (Bio-Rad, Philadelphia, PA, USA). Plasma glucose, cholesterol and triacylglycerol concentrations were measured using enzymatic assays (Beckman Coulter Diagnostics, Gladsville, NSW, Australia). Organs were dissected and weights obtained before being either snap frozen in liquid nitrogen or fixed in buffered formalin (10% vol./vol.).
Animal model
NOX inhibition GKT137831 is a specific inhibitor of both NOX1 and NOX4 [16, 17] . GKT137831 was administered by oral gavage as a delayed intervention at a dose of 30 mg kg −1 day −1 or 60 mg kg −1 day −1 from week 10 to week 20 of diabetes. All animals were randomly assigned to treatment groups.
Atherosclerotic plaque area quantification Assessment of plaque area was undertaken using en face analysis after being cleaned and stained with Sudan IV, as previously described, in a blinded fashion [18] .
Renal function variables Urinary albumin concentration was measured at 10 and 20 weeks after the induction of diabetes, using a mouse albumin ELISA (Bethyl Laboratories, Montgomery, TX, USA) [6, 19] . Urinary and serum creatinine concentrations were measured by HPLC [19, 20] . The urinary albumin/creatinine ratio (ACR) and creatinine clearance were calculated.
Quantitative RT-PCR Total RNA was extracted from aorta and kidneys with DNA-free RNA being reverse transcribed into cDNA [5, 6] . Expression of genes encoding members of the NOX family, Nox1, Nox2 (also known as Cybb), Nox4 and p47phox (also known as Ncf1), proinflammatory and profibrotic pathways, including Tnfα (also known as Tnf), Nfκ p65 (also known as Rela), Mcp-1 (also known as Ccl2), Vcam-1 (also known as Vcam1), Ctgf, fibronectin and collagen IV were analysed by quantitative RT-PCR using the Taqman system (ABI Prism 7500; Perkin-Elmer, Foster City, CA, USA). The primer and probe sequences have been published previously [19] [20] [21] [22] [23] .
Measurements of ROS and H 2 O 2 Tissue ROS production was measured in 10 mm segments of aorta and renal cortex using L-012 (Wako Chemicals, Richmond, VA, USA) at a concentration of 100 μmol/l, in the dark, after incubation at 37°C for 15 min and read on a fluorescence microplate reader at 400 nm. The generation of H 2 O 2 was measured in 10 mm segments of aorta and renal cortex samples by Amplex Red, using a commercial kit (Molecular Probes, Eugene, OR, USA) [5] . Cytosolic and mitochondrial extracts were isolated as previously described [24] . Fluorescence intensity was measured on a microplate at an excitation wavelength of 544 nm and an emission wavelength of 590 nm.
Immunohistochemistry Paraffin sections (4 μm) of kidney were used for histological stains using periodic acid-Schiff's reagent to assess mesangial expansion, as previously described [21, 25] . Immunohistochemical stains were performed on paraffin sections (4 μm) of aorta and kidney for nitrotyrosine, a marker of oxidative stress (rabbit polyclonal; Millipore, Billerica, MA, USA; 1:100), fibronectin, a marker of fibrosis (rabbit polyclonal; Abcam, Cambridge, AM USA; 1:200) and F4/80, a marker of macrophages (rat monoclonal; Abcam, Cambridge, AM, USA; 1:100) as previously described, and analysed in a blinded fashion [5, 26, 27] .
MCP-1, TNF-α, IL1-β, TGF-β, VEGF and MIF measurements Levels of aortic and/or kidney monocyte chemoattractant protein 1 (MCP-1), TNF-α, IL1-β, TGF-β, vascular endothelial growth factor (VEGF) and macrophage inhibitory factor (MIF) were measured as previously described [28] . In brief, whole-protein preparations were obtained [6] and measured following the manufacturer's instructions (MCP-1, TNF-α, TGF-β, IL1-β and VEGF, R&D Systems, Minneapolis, MN, USA; MIF, Wuhan USCN, China).
Statistical analysis Data were analysed for normality using the Shapiro-Wilk test before being analysed by either a oneor two-way ANOVA using SPSS Statistics version 20 (IBM, Armonk, NY, USA) with a least significant difference (LSD) post hoc test for multiple comparisons of the means. A p value <0.05 was considered statistically significant. Results are shown as mean ± SEM unless otherwise specified.
Results
Delayed NOX1/4 inhibition reverses urinary albumin excretion in diabetic mice We tested if delayed administration of GKT137831 in mice with established diabetic complications including atherosclerosis and renal disease could attenuate end-organ injury. After 20 weeks of diabetes, untreated diabetic ApoE −/− mice gained less body weight than their untreated control counterparts (Table 1) . Additionally, untreated diabetic mice had significant elevations in blood glucose, HbA 1c , cholesterol, triacylglycerol and LDL-cholesterol ( Table 1) . Administration of GKT137831 from week 10 to 20 of diabetes at both doses did not affect body weight, blood glucose, HbA 1c or circulating lipid concentrations (Table 1) . Interestingly, administration of GKT137831 at the lower 30 mg kg −1 day −1 dose significantly reduced total kidney/ body weight ratio compared with untreated ApoE −/− diabetic mice, but was ineffective at the higher 60 mg kg (Fig. 1a, b ).
Delayed inhibition of NOX1/4 attenuates renal NOX isoform gene expression and markers of ROS in diabetes
After 20 weeks of diabetes, ApoE −/− mice demonstrated a significant increase in the gene expression of Nox1, Nox4 and p47phox in the renal cortex, with no change in the expression of Nox2 ( Table 2 ). Administration of GKT137831 at the 30 mg kg −1 day −1 dose to diabetic ApoE −/− mice reduced the diabetes-induced increase in the gene expression of both Nox1 and Nox4, while the 60 mg kg
and Nox2 gene expression (Table 2) . Glomerular nitrotyrosine accumulation was significantly increased in untreated diabetic ApoE −/− mice after 20 weeks of diabetes, and this was not significantly altered in response to GKT137831 administration from week 10 to 20 of diabetes (Fig. 2a, (Fig. 2b, d ).
Delayed inhibition of NOX1/4 attenuates renal inflammation and renal fibrosis The diabetes-induced increase in mesangial expansion in untreated diabetic ApoE −/− mice after 20 weeks of diabetes was significantly attenuated by both doses of GKT137831, with the higher dose leading to a mesangial area approaching that seen in non-diabetic ApoE −/− mice (Fig. 3a, b) . Diabetes induced significant increases in protein concentrations of the proinflammatory factors MCP-1 and TNF-α and the profibrotic factors VEGF and TGF-β in the renal cortex (Fig. 3c, d , f, g). Furthermore, there were significant increases in the expression of the collagen IV gene and glomerular fibronectin protein staining in untreated ApoE −/− diabetic mice (Fig. 3e, h ). Delayed administration of GKT137831 at both doses significantly attenuated the diabetes-induced increase in MCP-1, TNF-α, VEGF and TGF-β concentrations, with the higher dose normalising protein concentrations to levels similar to those of the untreated non-diabetic ApoE −/− mice (Fig. 3c, d , f, g). Glomerular fibronectin protein levels were significantly reduced by the high dose of GKT137831 (60 mg kg
) and non-significantly reduced at the low dose (30 mg kg
) compared with untreated diabetic ApoE −/− mice (Fig. 3h, i) .
Delayed NOX1/4 inhibition demonstrates a dosedependent anti-atherosclerotic effect in diabetes After 20 weeks of diabetes, untreated diabetic ApoE −/− mice demonstrated a significant increase in plaque area compared with untreated ApoE −/− control mice (Fig. 4a, b, ESM Fig. 1 ).
Administration of GKT137831 to ApoE −/− mice from week 10 until week 20 of diabetes at a dose of 30 mg kg
significantly attenuated the development of atherosclerosis compared with untreated diabetic ApoE −/− mice, resulting in a 30% reduction in aortic arch and total aortic plaque area ( Fig. 4a, b) . However, the effect was less pronounced than when the compound was given in a preventive manner (Fig. 4a, b) . Interestingly, at the higher dose of 60 mg kg
GKT137831 was ineffective at preventing further development of atherosclerosis in the aortic arch and total aorta compared with untreated diabetic ApoE −/− mice (Fig. 4a, b) . ; 60 mg GKT, 60 mg kg , GKT137831 only resulted in a decrease in Nox2 and p47phox gene expression, with no change in gene expression of Nox1 (Table 3) . Administration of GKT137831 at the lower dose of 30 mg kg −1 day −1 significantly increased the gene expression of Nox4 in the aorta compared with untreated diabetic ApoE −/− mice (Table 3) . Nitrotyrosine was increased in the aorta of untreated diabetic ApoE −/− mice compared with control ApoE −/− mice (Fig. 5a ). Administration of GKT137831 at both doses resulted in a significant reduction in aortic nitrotyrosine accumulation in the diabetic mice (Fig. 5a) (Fig. 5b) . GKT137831 administration at the higher dose of 60 mg kg −1 day −1 had no effect on H 2 O 2 production (Fig. 5b) . In turn, measurements of aortic ROS production identified a non-significant increase in ROS production in untreated ApoE −/− diabetic mice, which was attenuated with administration of GKT137831 at 60 mg kg −1 day −1 but not at 30 mg kg −1 day −1 (Fig. 5d) .
Aortic inflammation and chemotaxis is reduced in response to pharmacological inhibition of NOX1/4 in ; 60 mg GKT, 60 mg kg
diabetes After 20 weeks of diabetes, ApoE −/− mice demonstrated a significant increase in the protein levels of TNF-α, IL1-β and MCP-1 (Fig. 6a-c) . Measurements of the proinflammatory and pro-atherogenic MIF in aortic homogenates identified a significant diabetes-induced increase (Fig. 6d) , which correlated with an increase in macrophage accumulation within the aortic wall (Fig. 6e, f) . Delayed administration of GKT137831 significantly reduced MCP-1 protein concentration only at the lower dose of 30 mg kg −1 day −1 (Fig. 6c) . Treatment with the higher dose of 60 mg kg −1 day −1 was associated with elevations in protein levels of TNF-α and IL-1β (Fig. 6a, b) . GKT137831 administration significantly elevated MIF concentration at the higher dose (60 mg kg −1 day −1 ) with a non-significant reduction when administered at the lower dose (30 mg kg −1 day −1 ; ), but no clear effect on vascular macrophage accumulation was seen with the higher dose of 60 mg kg −1 day −1 (Fig. 6e, f) .
Discussion
There is increasing evidence that NOX-derived ROS formation plays a key role in the development and progression of micro-and macrovascular complications, in particular in the context of diabetes. We have previously shown that global deletion of Nox1 attenuated diabetes-associated atherosclerosis in a shorter-duration model of 10 weeks of diabetes via effects on inflammation and plaque remodelling. Preventive treatment with a novel NOX1/4 inhibitor GKT137831 in diabetic ApoE −/− mice similarly attenuated plaque development in association with increased plaque stability, as assessed by a reduced number of necrotic cores, attenuated macrophage accumulation and reduced vascular inflammation [5, 12] . Moreover, recently we have identified that NOX4 plays a protective role in diabetes-associated atherosclerosis [28] . The effects of NOX1/4 inhibition were different in the kidney, further emphasising tissue-specific effects of NOX isoform inhibition. We have previously shown, using global Nox4-knockout mice, that deletion of NOX4 affords renoprotective effects in diabetic kidney disease. In addition, podocyte-specific Nox4 deletion was shown to be ) non-significantly reduced the concentration of TNF-α, IL-1β and MIF, and significantly reduced MCP-1 (a-d). In contrast, GKT137831 administration at the higher dose (60 mg kg
) significantly increased the concentration of TNF-α, IL-1β and MIF, with no effect on MCP-1 (a-d). Similarly, macrophage accumulation was increased in response to diabetes, but GKT137831 did ) from week 10 to 20 attenuated this variable (a, c). Aortic H 2 O 2 production was significantly reduced in untreated diabetic mice and was significantly restored above control levels with GKT137831 at 30 mg kg ; 60 mg GKT, 60 mg kg
renoprotective in diabetic kidney disease [6, 29] , whereas Nox1 deletion had no impact [6] . Furthermore, NOX1/4 inhibition with GKT137831 has shown renoprotective effects including reduction in albuminuria and attenuation of renal structural injury and inflammation after 20 weeks of treatment [6] . Indeed, the preventive renoprotective effect of GKT137831 has been shown in at least three different animal models of diabetic nephropathy, including in ApoE −/− mice with STZ-induced diabetes [25] , in the Akita mouse [30] and in the OVE26 mouse [31] , as reflected by reduced albuminuria, renal fibrosis and inflammation. Here, we report that delayed intervention with two doses of GKT137831 attenuates established renal disease in diabetes as assessed by lower albuminuria, a decrease in renal fibrosis and a reduction in renal inflammation. Indeed, delayed intervention with GKT137831 reversed the overt albuminuria observed after 10 weeks of diabetes by at least 50% by the end of the study. Renal Nox4 gene expression was significantly reduced with both doses of GKT137831 and this may reflect reduced renal injury. Similar effects were recently reported in microglial and Müller cells exposed to hypoxia and treated with GKT137831 [32] . It is therefore possible that reduced expression and enzyme activity both contribute to the pharmacological effects of NOX inhibitors. Furthermore, the higher dose of GKT137831 appeared to have a more potent effect on some of the renal variables examined, further supporting the deleterious role of NOX4 in diabetic nephropathy.
To assess the vasculoprotective effects of pharmacological NOX1/4 inhibition in a clinically more relevant context, we examined the impact of delayed intervention with the NOX1/4 inhibitor GKT137831 in established disease. Indeed, a dose of 30 mg kg −1 day −1 significantly attenuated atherosclerosis development in mice with established diabetic vascular disease. However, the higher dose of 60 mg kg −1 day −1 failed to reduce plaque area. At this dose, it is postulated that GKT137831 may have a more profound effect on vascular NOX4 activity, thereby offsetting the beneficial effects conferred by NOX1 inhibition. Interestingly, delayed intervention with both doses of GKT137831 was associated with reduced aortic nitrotyrosine accumulation, consistent with a beneficial effect of vascular NOX1 inhibition. Interestingly, Nox4 expression was already reduced in the aorta of diabetic ApoE −/− mice. The lower dose of 30 mg kg −1 day −1 increased Nox4 expression, whereas the higher dose of 60 mg kg −1 day −1 had no effect. It is unclear if these differences contribute to the lack of atheroprotection seen with the higher dose. These findings are consistent with recent studies that have observed that NOX4 is atheroprotective [28] . It is, however, important to interpret gene expression results with caution, as Nox1 and Nox2 are mainly regulated at the post-translational level. The atheroprotective role of NOX4 can potentially explain the lack of atheroprotection at the high dose of GKT137831. Also, the diseased aorta undergoes substantial remodelling in this long-term model, with atherosclerotic plaques covering close to 30% of the luminal area. Therefore, tissue heterogeneity and increased acellular material inevitably reduce the ability to interpret these gene expression findings.
The renal cortex of untreated diabetic mice showed a depletion of H 2 O 2. This finding has been previously reported in the diabetic kidney [33] , although this phenomenon remains to be fully explained. Reductions in H 2 O 2 levels most likely arise through reduced production by H 2 O 2 generators such as NOX4, reduced dismutation from superoxide by the superoxide dismutase (SOD) enzymes, or increased removal by the peroxidase enzymes, of which there are several. The fact that Nox4 expression increased in the diabetic ApoE −/− kidney in this study may seem contradictory. However, two reports claim that NOX4 contributes to the generation of superoxide under some disease conditions [34, 35] , highlighting the important nature of changes in ROS production between health and disease. H 2 O 2 levels were also observed to increase in the aorta after 30 mg kg −1 day −1 GKT137831 treatment.
One possible explanation is that the activity of peroxidases is reduced by NOX1/4 inhibition in the diabetic aorta, resulting in a lower rate of H 2 O 2 removal to water. Furthermore, the generation of H 2 O 2 occurs via multiple sources, not only via dismutation of superoxide by the SOD enzymes. Therefore, one cannot assume that an increase in superoxide would always lead to an increase in H 2 O 2 as this reaction also relies on the activity of various SOD enzymes, which are altered in the diabetic milieu [36] . These results demonstrate that blocking NOX1/4 in established micro-and macrovascular complications of diabetes can provide concomitant athero-and renoprotection in diabetes. Furthermore, our results suggest that there are tissue-and dose-dependent effects of GKT137831 that need to be further explored. The degree of relative inhibition of NOX4 vs NOX1 appears to be particularly important in the macrovasculature, although this issue does not appear as important in the kidney.
Preliminary results of a short-term phase 2a clinical trial evaluating the safety and efficacy of GKT137831 in patients with diabetic kidney disease have been reported [37] . This report indicates that GKT137831 was very well tolerated and showed pharmacodynamic activity on markers of inflammation and liver injury. However, GKT137831 treatment for 12 weeks did not improve renal outcomes including albuminuria. While the reported safety and pharmacodynamic results appear encouraging, it will be important to assess these clinical results further and to determine specifically if treatment duration, dose, concomitant medications or certain characteristics of the patient population might have played a role.
Taken together, the available data suggest that selective inhibition of NOX1 may be particularly effective to specifically prevent diabetes-induced vascular disease in conduit arteries and the retina [32] . NOX inhibitors with a broader selectivity profile, including NOX1, NOX4 and, possibly, NOX5 may represent more attractive therapeutic options in patients with associated kidney disease. Therefore, NOX inhibitors with specific selectivity profiles should be evaluated in carefully defined patient populations. Given the dose-and tissue-specific effects of the dual NOX1/4 inhibitor GKT137831, future studies need to define the relative balance of NOX1 vs NOX4 inhibition in both the micro-and macrovasculature in diabetes. Any clinical study evaluating an agent such as GKT137831 should include concomitant assessment of both renal and cardiovascular endpoints.
